Homepage > Company > Media > Pharma News > 2019 > FDA Approves Abrilada

FDA Approves Abrilada

The U.S. Food and Drug Administration (FDA) approved Abrilada (adalimumab-afzb), the 5th biosimilar to U.S.-licensed Humira (adalimumab). This approval marks the 25th biosimilar.

A biosimilar is a biological product that is highly similar to an existing FDA-approved biological product, known as a reference product. The biosimilar must also have no clinically meaningful differences in terms of safety and effectiveness from the reference product. All FDA-approved biosimilar products meet the FDA’s strict standards for approval. Patients and healthcare providers can rely on the safety and effectiveness of the biosimilar or interchangeable product just as they would for the reference product.

November 22, 2019

https://www.pharmoutsourcing.com/

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.